Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome (IBS): an evidence-based review
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Post-infectious irritable bowel syndrome (PI-IBS) prevalence, small intestinal bacterial overgrowth (SIBO), altered microbiota, low-grade inflammation, and antibiotic therapy in IBS are all controversial issues. AIMS: To conduct an evidence-based review of these factors. METHODS: A review of the literature was carried out up to July 2012, with the inclusion of additional articles as far as August 2013, all of which were analyzed through the Oxford Centre for Evidence-Based Medicine (OCEBM) system. RESULTS: 1.There is greater SIBO probability in IBS when breath tests are performed, but prevalence varies widely (2-84%). 2.The gut microbiota in individuals with IBS is different from that in healthy subjects, but a common characteristic present in all the patients has not been established. 3.The incidence and prevalence of PI-IBS varies from 9-10% and 3-17%, respectively, and the latter decreases over time. Bacterial etiology is the most frequent but post-viral and parasitic cases have been reported. 4.A sub-group of patients has increased enterochromaffin cells, intraepithelial lymphocytes, and mast cells in the intestinal mucosa, but no differences between PI-IBS and non-PI-IBS have been determined. 5.Methanogenic microbiota has been associated with IBS with constipation. 6.Rifaximin at doses of 400mg TID/10days or 550mg TID/14days is effective treatment for the majority of overall symptoms and abdominal bloating in IBS. Retreatment effectiveness appears to be similar to that of the first cycle. CONCLUSIONS: Further studies are required to determine the nature of the gut microbiota in IBS and the differences in low-grade inflammation between PI-IBS and non-PI-IBS. Rifaximin has shown itself to be effective treatment for IBS, regardless of prior factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barbara, G., Stanghellini, V., De Giorgio, R., Cremon, C., Cottrell, G. S., Santini, D., Pasquinelli, G., Morselli-Labate, A. M., Grady, E. F., Bunnett, N. W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.055 · Cited by 1,475
Spiller, R. C., Jenkins, D., Thornley, J. P., Hebden, J. M., Wright, T., Skinner, M., & Neal, K. R. (2000) · Gut · doi:10.1136/gut.47.6.804 · Cited by 1,155 · cited 3×
“In addition, some studies have demonstrated a rise in the number of IEL in both IBS-D and PI-IBS, mainly after acute gastroenteritis due to C. jejuni or Shigella.95,111,117 Nevertheless, it is not completely known if there is also an increase in T lymphocytes in non PI-IBS.”
Rajilić–Stojanović, M., Biagi, E., Heilig, H. G. H. J., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.043 · Cited by 1,041
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 4×
“They show that rifaximin at a dose of 550 mg TID for 14 days in patients with IBS-Non C by Rome II criteria resulted in a greater proportion of patients with adequate relief from IBS symptoms, abdominal bloating, daily symptom intensity, abdominal pain, and stool consistency.(134) In the follow-up at 10 weeks post-tre…”
InfluentialKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835 · cited 1×
“demonstrated that 17 taxas are associated with a slow colonic transit time (including those of the following phylotypes: Euryarchaeota, those of the class: Methanobacteria, and those of the families: Methanobacteriaceae and Desulfohalobiaceae).(60) Likewise, the presence of Proteobacteria is described as being associa…”
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833 · cited 2×
“In addition, some studies have demonstrated a rise in the number of IEL in both IBS-D and PI-IBS, mainly after acute gastroenteritis due to C. jejuni or Shigella.95,111,117 Nevertheless, it is not completely known if there is also an increase in T lymphocytes in non PI-IBS.”
The role of psychological and biological factors in postinfective gut dysfunction
Gwee, K.-A., Leong, Y.-L., Graham, C., McKendrick, M. W., Collins, S. M., Walters, S. J., Underwood, J. E., & Read, N. W. (1999) · Gut · doi:10.1136/gut.44.3.400 · Cited by 764
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome
Saulnier, D. M., Riehle, K., Mistretta, T., Diaz, M., Mandal, D., Raza, S., Weidler, E. M., Qin, X., Coarfa, C., Milosavljevic, A., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.072 · Cited by 672
Dunlop, S. P., Jenkins, D., Neal, K. R., & Spiller, R. C. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.028 · Cited by 583
Törnblom, H., Lindberg, G., Nyberg, B., & Veress, B. (2002) · Gastroenterology · doi:10.1053/gast.2002.37059 · Cited by 516
Pimentel, M., Lin, H. C., Enayati, P., van den Burg, B., Lee, H.-R., Chen, J. H., Park, S., Kong, Y., & Conklin, J. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00574.2004 · Cited by 508
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Increased mast cells in the irritable bowel syndrome
O’Sullivan, Clayton, Breslin, Harman, Bountra, Mclaren, & O’Morain (2000) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2000.00221.x · Cited by 480
tana, C., umesaki, Y., imaoka, A., handa, T., kanazawa, M., & fukudo, S. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01427.x · Cited by 474 · cited 2×
“The microbiota was analyzed with molecular methods in the majority of the studies, whereas just fecal culture was used in 2,(39,40) and both methodologies were used in 4 studies.(42,48,51,58) Even though the majority of the studies analyzed the composition of the microbiota in samples of fecal matter, the microbial co…”
THABANE, M., KOTTACHCHI, D. T., & MARSHALL, J. K. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03399.x · Cited by 466
Carroll, I. M., Ringel‐Kulka, T., Siddle, J. P., & Ringel, Y. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01891.x · Cited by 425
Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis
Wang, L.-H., Fang, X.-C., & Pan, G.-Z. (2004) · Gut · doi:10.1136/gut.2003.021154 · Cited by 387
Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum
Guilarte, M., Santos, J., de Torres, I., Alonso, C., Vicario, M., Ramos, L., Martinez, C., Casellas, F., Saperas, E., & Malagelada, J. R. (2007) · Gut · doi:10.1136/gut.2006.100594 · Cited by 385
Dunlop, S. P., Jenkins, D., & Spiller, R. C. (2003) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07542.x · Cited by 359
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351 · cited 1×
“Two systematic reviews with a meta-analysis that included more than 3,400 subjects and compared patients with IBS and healthy controls showed that the breath tests for SIBO were abnormal in the patients, with a 4-times higher probability than the controls.(3,17) An extensive bibliographic search was carried out in bot…”
Sharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344 · cited 1×
“Likewise, the outcome variables analyzed were very different in each of the studies, from global IBS improvement to improvement of secondary symptoms such as pain and/or abdominal bloating, to the frequency and consistency of bowel movements.(131,132,134) The effect of rifaximin on GBT(136,137) or LBT(33) has been eva…”
Cremon, C., Gargano, L., Morselli-Labate, A. M., Santini, D., Cogliandro, R. F., De Giorgio, R., Stanghellini, V., Corinaldesi, R., & Barbara, G. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.94 · Cited by 342
Terminal ileal mucosal mast cells in irritable bowel syndrome
Weston, A. P., Biddle, W. L., Bhatia, P. S., & Miner, P. B. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303164 · Cited by 338 · cited 2×
“The rise in the number of mast cells had been previously described by Weston et al. in biopsies of the terminal ileum in patients with IBS, compared with the control group, but no differentiation was made between PI-IBS and non PIIBS.93 Other researchers later confirmed the increase in the number of these cells in IBS…”
Mättö, J., Maunuksela, L., Kajander, K., Palva, A., Korpela, R., Kassinen, A., & Saarela, M. (2005) · FEMS Immunology & Medical Microbiology · doi:10.1016/j.femsim.2004.08.009 · Cited by 301 · cited 2×
“The microbiota was analyzed with molecular methods in the majority of the studies, whereas just fecal culture was used in 2,(39,40) and both methodologies were used in 4 studies.(42,48,51,58) Even though the majority of the studies analyzed the composition of the microbiota in samples of fecal matter, the microbial co…”
Kerckhoffs, A. P., Samsom, M., Rest, M. E. V. D., Vogel, J. D., Knol, J., Ben-Amor, K., & Akkermans, L. M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2887 · Cited by 289
Yu, D., Cheeseman, F., & Vanner, S. (2011) · Gut · doi:10.1136/gut.2009.205476 · Cited by 284
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283 · cited 3×
“In 2 later systematic reviews with meta-analyses published 2 years apart, the second one with 10 times more patients treated with rifaximin vs placebo, it was concluded, and with a good level of evidence, that the antibiotic at doses of 400 to 550 mg, 2 to 3 times/day, was twice as effective as the placebo at improvin…”
WALKER, M. M., TALLEY, N. J., PRABHAKAR, M., PENNANEAC’H, C. J., ARO, P., RONKAINEN, J., STORSKRUBB, T., HARMSEN, W. S., ZINSMEISTER, A. R., & AGREUS, L. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.03937.x · Cited by 261
Duboc, H., Rainteau, D., Rajca, S., Humbert, L., Farabos, D., Maubert, M., Grondin, V., Jouet, P., Bouhassira, D., Seksik, P., et al. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01893.x · Cited by 256
Villani, A., Lemire, M., Thabane, M., Belisle, A., Geneau, G., Garg, A. X., Clark, W. F., Moayyedi, P., Collins, S. M., Franchimont, D., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.049 · Cited by 244
A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome
Codling, C., O’Mahony, L., Shanahan, F., Quigley, E. M. M., & Marchesi, J. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0934-x · Cited by 243
Marshall, J. K., Thabane, M., Borgaonkar, M. R., & James, C. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.11.025 · Cited by 241
Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota
Noor, S. O., Ridgway, K., Scovell, L., Kemsley, E. K., Lund, E. K., Jamieson, C., Johnson, I. T., & Narbad, A. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-134 · Cited by 227
Marshall, J. K., Thabane, M., Garg, A. X., Clark, W. F., Moayyedi, P., Collins, S. M., & Walkerton Health Study Investigators (2010) · Gut · doi:10.1136/gut.2009.202234 · Cited by 227
Intestinal microecology and quality of life in irritable bowel syndrome patients
Si, J.-M. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i12.1802 · Cited by 218 · cited 2×
“Twenty-six published articles were identified that studied the composition of the microbiota in patients with IBS; 24 in the initial search and 2 from other sources.(39,40) All of them are case-control studies conducted in Europe, Asia, and the United States; none from Latin America or Africa.”
Carroll, I. M., Chang, Y.-H., Park, J., Sartor, R. B., & Ringel, Y. (2010) · Gut Pathogens · doi:10.1186/1757-4749-2-19 · Cited by 203 · cited 1×
“The microbiota was analyzed with molecular methods in the majority of the studies, whereas just fecal culture was used in 2,(39,40) and both methodologies were used in 4 studies.(42,48,51,58) Even though the majority of the studies analyzed the composition of the microbiota in samples of fecal matter, the microbial co…”
Parkes, G. C., Rayment, N. B., Hudspith, B. N., Petrovska, L., Lomer, M. C., Brostoff, J., Whelan, K., & Sanderson, J. D. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01803.x · Cited by 200
PARK, J. H., RHEE, P., KIM, H. S., LEE, J. H., KIM, Y., KIM, J. J., & RHEE, J. C. (2006) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.04143.x · Cited by 196
Lee, K. J., Kim, Y. B., Kim, J. H., Kwon, H. C., Kim, D. K., & Cho, S. W. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05574.x · Cited by 171 · cited 1×
“observed a greater number of enterochromaffin cells, IEL, and mast cells in rectal biopsies in PI-IBS patients, compared with non PI-IBS patients and healthy controls.(108) An increase in the number of mast cells in non PI-IBS was observed only in those patients with IBS-D, not in patients with IBS-C or IBS-M.”
Lyra, A., Rinttilä, T., Nikkilä, J., Krogius-Kurikka, L., Kajander, K., Malinen, E., Mättö, J., Mäkelä, L., & Palva, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5936 · Cited by 160
Pimentel, M., Chatterjee, S., Chow, E. J., Park, S., & Kong, Y. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9104-6 · Cited by 160
Maukonen, J., Satokari, R., Mättö, J., Söderlund, H., Mattila-Sandholm, T., & Saarela, M. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46134-0 · Cited by 156
Yang, J., Lee, H.-R., Low, K., Chatterjee, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9839-8 · Cited by 129
Thabane, M., Simunovic, M., Akhtar-Danesh, N., Garg, A. X., Clark, W. F., Collins, S. M., Salvadori, M., & Marshall, J. K. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.74 · Cited by 120
Grover, M., Kanazawa, M., Palsson, O. S., Chitkara, D. K., Gangarosa, L. M., Drossman, D. A., & Whitehead, W. E. (2008) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2008.01142.x · Cited by 111
Schwille-Kiuntke, J., Enck, P., Zendler, C., Krieg, M., Polster, A. V., Klosterhalfen, S., Autenrieth, I. B., Zipfel, S., & Frick, J.-S. (2011) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01779.x · Cited by 110 · cited 13×
“76 The above allows us to conclude that the incidence and prevalence of PI-IBS are variable and even though the bacterial etiology has been studied the most, it appears that viruses such as the Norovirus and parasites such as Giardia may also be related to PI-IBS.”
InfluentialÖhman, L., Isaksson, S., Lundgren, A., Simrén, M., & Sjövall, H. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00410-6 · Cited by 98
Braak, B., Klooker, T. K., Wouters, M. M., Welting, O., van der Loos, C. M., Stanisor, O. I., van Diest, S., van den Wijngaard, R. M., & Boeckxstaens, G. E. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.54 · Cited by 93 · cited 2×
“In that study, the difference between PI-IBS and non PI-IBS was not specifically analyzed, but rather the patients with acute and gradual IBS onset were compared, and a lower number of macrophages was observed in those with gradual IBS onset.(115) It is likely that the sudden onset group corresponds to PI-IBS, but we…”
Peralta, S., Cottone, C., Doveri, T., Almasio, P. L., & Craxi, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2628 · Cited by 88
Kim, H. S., Lim, J. H., Park, H., & Lee, S. I. (2010) · Yonsei Medical Journal · doi:10.3349/ymj.2010.51.1.45 · Cited by 85 · cited 2×
“In addition, some studies have demonstrated a rise in the number of IEL in both IBS-D and PI-IBS, mainly after acute gastroenteritis due to C. jejuni or Shigella.95,111,117 Nevertheless, it is not completely known if there is also an increase in T lymphocytes in non PI-IBS.”
Disease burden of post-infectious irritable bowel syndrome in The Netherlands
HAAGSMA, J. A., SIERSEMA, P. D., DE WIT, N. J., & HAVELAAR, A. H. (2010) · Epidemiology and Infection · doi:10.1017/s0950268810000531 · Cited by 85 · cited 3×
“The incidence of clinical symptoms of IBS after a gastrointestinal infection has been reported at an average of 9-10% based on 2 systematic reviews, but varies depending on the case from 4 to 36%.(65,67) There are no differences if IBS develops after an acute gastroenteritis episode during epidemics, due to isolated i…”
InfluentialSchmulson, M., & Chang, L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04637.x · Cited by 70 · cited 3×
“In vitro it induces CYP3A4, but its interaction with other medications is almost null.(129) In the selected reviews, a short cycle of non-absorbable antibiotics, like rifaximin, has been recommended for improving global IBS symptoms.”
InfluentialSelf-citationSpiegel, B. M. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.030 · Cited by 67
Weinstock, L. B., Fern, S. E., & Duntley, S. P. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-0021-0 · Cited by 56
Rezaie, A., Nikfar, S., & Abdollahi, M. (2010) · Archives of Medical Science · doi:10.5114/aoms.2010.13507 · Cited by 40 · cited 2×
“In 2 later systematic reviews with meta-analyses published 2 years apart, the second one with 10 times more patients treated with rifaximin vs placebo, it was concluded, and with a good level of evidence, that the antibiotic at doses of 400 to 550 mg, 2 to 3 times/day, was twice as effective as the placebo at improvin…”
Esposito, I. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.13.6016 · Cited by 28 · cited 1×
“Despite its apparently being a more precise test, it has been employed in fewer studies.(24,27,32,36) Sucrose, another substrate that is totally absorbed in the small bowel and therefore theoretically more accurate, was used in only one of the selected studies.”
Cited by
Stress and the Microbiota–Gut–Brain Axis in Visceral Pain: Relevance to Irritable Bowel Syndrome
Moloney, R. D., Johnson, A. C., O'Mahony, S. M., Dinan, T. G., Greenwood‐Van Meerveld, B., & Cryan, J. F. (2016) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12490 · Cited by 386
Gut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
The role of mast cells in functional GI disorders
Wouters, M. M., Vicario, M., & Santos, J. (2016) · Gut · doi:10.1136/gutjnl-2015-309151 · Cited by 308
Schmulson, M. J., & Frati-Munari, A. C. (2019) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2018.02.008 · Cited by 14
Self-citation
Metadata
- Authors
- Schmulson, M., Bielsa, M. V., Carmona-Sánchez, R., Hernández, A., López-Colombo, A., Vidal, Y. L., Peláez-Luna, M., Remes-Troche, J. M., Tamayo, J. L., & Valdovinos, M. A.
- Venue
- Revista de Gastroenterología de México (English Edition)
- Publisher
- Elsevier BV
- Published
- 2014-04
- Volume
- 79
- Issue
- 2
- Pages
- 96-134
- ISSN
- 2255-534X (ISSN-L)
- OpenAlex
- W2108206778
- Cited by
- 38
- References
- 59
- FWCI
- 6.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.